<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590979</url>
  </required_header>
  <id_info>
    <org_study_id>Bekheit-Ranolazine</org_study_id>
    <nct_id>NCT01590979</nct_id>
  </id_info>
  <brief_title>Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation</brief_title>
  <official_title>Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation Rates in Post-Operative Cardiac Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the prophylactic effects of Ranolazine on new onset
      atrial fibrillation in post-operative coronary artery bypass graft and valve surgery patient
      population at Staten Island University hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is a common complication of cardiac surgery. It has been shown that
      the onset of AF increases in post-operative cardiac surgery population. The rate of AF after
      coronary artery bypass graft (CABG) procedure range from 10-65% and from 37-50% after valve
      surgery. Rates of new onset AF are lower for CABG compared to valve procedures. The
      pathophysiology of post-operative AF is not well elucidated. It has been postulated that
      pre-operative factors such as age, past medical history, operative and post-operative
      remodeling of the coronary system and hemodynamic pressure changes may contribute to
      post-operative AF.

      Ranolazine is currently approved as an antianginal drug. The antianginal properties of the
      drug are due to inhibition of the late inward sodium current. Through the same mechanism it
      has been demonstrated in animal experiments and human studies that it can prevent atrial and
      ventricular arrhythmias.

      Therefore it is important to prevent or minimize the incidence of new onset post-operative AF
      in post-surgical population.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to slow rate of accrual resulting in a sample size.
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of New Onset Atrial Fibrillation Rate in Post-Operative Cardiac Surgery Patients</measure>
    <time_frame>3 weeks after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Atrial Fibrillation New Onset</condition>
  <condition>Hemorrhage</condition>
  <condition>Prolonged QTc Interval</condition>
  <condition>Ventricular Tachycardia</condition>
  <condition>Medical Care; Complications, Late Effect of Complications</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>1000mg, two times a day, 12 hour intervals</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>RANEXAÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>two times a day, 12 hour intervals</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female candidates (18 years of age and older) undergoing coronary bypass
             grafting surgery or valve repair or replacement - Aortic or Tricuspid or Pulmonary
             valves

          -  Patients who are not previously on Ranolazine

          -  Do not have a history of arrhythmia and are not on any antiarrhythmic therapy

          -  Patients with QTc on a 12 lead EKG of less than or equal to 460 ms

          -  Patients with estimated Glomerular Filtration Rate (GFR) greater than 30 mL/min/1.73
             m2 on the initial lab work

          -  Available at least 48 hours before surgery

        Exclusion criteria:

          -  Patients who are not undergoing above surgeries

          -  Patients undergoing surgery for mitral valve replacement/repair

          -  Patient with cirrhosis

          -  Pregnant patients

          -  Patients with chronic atrial fibrillation

          -  Patients who had prior adverse drug reactions or allergies to Ranolazine

          -  Patients who are already taking Ranolazine prior to the study

          -  Patient who are reported HIV Positive (as there are antiretroviral drug interactions)

          -  Patients who are on drugs listed in Appendix A prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soad Bekheit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staten Island University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Staten Island University Hosptial</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://preview.ncbi.nlm.nih.gov/pubmed?term=Murdock%20DK%2C%20Kersten%20M%2C%20Kaliebe%20J%2C%20Larrain%20G</url>
    <description>The conversion of paroxysmal or initial onset atrial fibrillation with oral Ranolazine: Implications for a new &quot;pill-in-pocket&quot; approach in structural heart disease.</description>
  </link>
  <link>
    <url>http://preview.ncbi.nlm.nih.gov/pubmed?term=21726841</url>
    <description>Comparison of effectiveness and safety of Ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting.</description>
  </link>
  <link>
    <url>http://preview.ncbi.nlm.nih.gov/pubmed?term=21421082</url>
    <description>Electrophysiologic basis for the antiarrhythmic actions of Ranolazine. Heart Rhythm.</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <results_first_submitted>September 8, 2016</results_first_submitted>
  <results_first_submitted_qc>February 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2017</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Soad Bekheit</investigator_full_name>
    <investigator_title>Director of Electrophysiology Lab</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation New Onset</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>CABG</keyword>
  <keyword>valve repair/replacement</keyword>
  <keyword>Cardiac Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
Ranolazine: 1000mg, two times a day, 12 hour intervals</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
Placebo: two times a day, 12 hour intervals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
Ranolazine: 1000mg, two times a day, 12 hour intervals</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
Placebo: two times a day, 12 hour intervals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="11.7"/>
                    <measurement group_id="B2" value="62.9" spread="11.1"/>
                    <measurement group_id="B3" value="64.3" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of New Onset Atrial Fibrillation Rate in Post-Operative Cardiac Surgery Patients</title>
        <time_frame>3 weeks after surgery</time_frame>
        <population>Fifty-four patients were randomized with a mean follow-up of 25 months and none were lost to follow-up. The study was terminated due to slow rate of accrual resulting in a sample size of 27 ranolazine and 27 placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
Ranolazine: 1000mg, two times a day, 12 hour intervals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
Placebo: two times a day, 12 hour intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Onset Atrial Fibrillation Rate in Post-Operative Cardiac Surgery Patients</title>
          <population>Fifty-four patients were randomized with a mean follow-up of 25 months and none were lost to follow-up. The study was terminated due to slow rate of accrual resulting in a sample size of 27 ranolazine and 27 placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post op (days 1-6); hospital discharge; Post -op follow up (2-3 weeks); Follow up call (day 28).</time_frame>
      <desc>Patients were given a medication log post discharge to note when medication was taken and to note any other comments related to how they were feeling.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
Ranolazine: 1000mg, two times a day, 12 hour intervals</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
Placebo: two times a day, 12 hour intervals</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to insufficient accrual rate the study was stopped before the recruitment total was met. Thus, a major limitation is small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Soad Bekheit, MD</name_or_title>
      <organization>Staten Island University Hospital, Northwell Health</organization>
      <phone>718-226-6629</phone>
      <email>msills@northwell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

